Bristol Myers Squibb (CELG-RI) Net Cash Flow Growth (3y) (2012 - 2026)
Bristol Myers Squibb (CELG-RI) Net Cash Flow Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 38.95% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -49.89% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 33.59% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 37.67% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -129.17% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -10.13% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -98.96% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -51.84% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 8.91% |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | -11.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.43% |
| Mar 31, 2026 | -26.50% |
| Dec 31, 2025 | -84.99% |
| Sep 30, 2025 | 45.21% |
| Jun 30, 2025 | 44.84% |
| Mar 31, 2025 | 31.32% |
| Dec 31, 2024 | 74.32% |
| Sep 30, 2024 | -15.40% |
| Jun 30, 2024 | -277.98% |
| Mar 31, 2024 | 16.03% |
| Dec 31, 2023 | 40.59% |
| Sep 30, 2023 | -15.39% |
| Jun 30, 2023 | -29.10% |
| Mar 31, 2023 | -27.71% |
| Dec 31, 2022 | 27.49% |
| Sep 30, 2022 | -50.29% |
| Jun 30, 2022 | -27.52% |
| Mar 31, 2022 | -83.19% |
| Dec 31, 2021 | -31.31% |
| Sep 30, 2021 | 82.64% |